A new poll finds that many Americans remain hesitant to buy electric vehicles. The AP-NORC/EPIC poll found only about 2 in 10 ...

(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Adolescents and young adults with preexisting autoimmune disease are more likely to develop type 1 diabetes than those ...

Băi wén bù rú yī jiàn“Seeing for oneself is a hundred times better than hearing from others.”Chinese Proverb from the Book of ...

Biosimilars saved Italy €3.1 billion in drug spending over a decade as uptake reached 80% of biologic use, according to the ...

Biocon Biologics recently announced that it would manufacture and supply insulin glargine pens to Civica under a multi-year ...

The United States Rapid Acting Insulin Market is poised for significant growth, increasing from US$ 2.32 Billion in 2024 to US$ 3.40 Billion by 2033, with a CAGR of 4.33%. Key growth drivers include ...

Prescriptions for the insulin glargine biosimilar Semglee increased after it was granted interchangeable status with its reference product, Lantus. Increases were seen across retail, mail order, and ...

California's first insulin pens will be for sale two years after the governor’s promised delivery date in 2024.